<DOC>
	<DOCNO>NCT02232178</DOCNO>
	<brief_summary>Assess pharmacokinetic profile 2 dos XaraColl® implant open laparotomy hernioplasty ass relative bioavailability Xaracoll compare local bupivacaine infiltration .</brief_summary>
	<brief_title>Pharmacokinetics , Relative Bioavailability Safety Xaracoll Implant</brief_title>
	<detailed_description>Inguinal hernioplasty common surgery . Common surgical method use include laparoscopic open placement synthetic mesh . Managing postoperative pain prevent morbidity open mesh hernioplasty remain considerable medical challenge . Bupivacaine local anesthetic ( pain medicine ) establish safety profile . Collagen protein find mammal . The Xaracoll implant thin flat sponge make collagen come cow tendon contain bupivacaine . When inserted surgical site , collagen break bupivacaine release surgical site provide postoperative pain control . This study assess pharmacokinetic profile 2 dos XaraColl implant open laparotomy hernioplasty ass relative bioavailability Xaracoll implant compare local bupivacaine infiltration .</detailed_description>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Man woman ≥ 18 year age 2 . Has plan unilateral inguinal hernioplasty ( open laparotomy , tension free technique ) 3 . If female , nonpregnant 1 . Scheduled bilateral inguinal hernioplasty significant concomitant surgical procedure 2 . Has undergone major surgery within 3 month schedule hernioplasty plan undergo another laparotomy procedure within 30 day postoperatively 3 . Has clinically significant unstable cardiac , neurological , immunological , renal , hepatic hematological disease condition , opinion investigator , could compromise patient 's welfare , ability communicate study staff otherwise contraindicate study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>unilateral inguinal hernioplasty</keyword>
</DOC>